Peptide-based immunotherapy: A novel strategy for allergic disease

Expert Review of Vaccines

Volumn 4, Issue 6, 2005, Pages 881-889

  Ali, F Runa ^a   Larché, Mark ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Allergy; Asthma; Cytokines; Immunotherapy; Peptides; T cells; Tolerance

Indexed keywords

ALLERVAX; BEE VENOM; CD4 ANTIGEN; EPITOPE; HLA DR ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; IMMUNOMODULATING AGENT; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; PEPTIDE DERIVATIVE; POLLEN ANTIGEN; TRANSFORMING GROWTH FACTOR BETA;

ALLERGY; CAT; DRUG SAFETY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INSECT ALLERGY; NONHUMAN; POLLEN ALLERGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; T LYMPHOCYTE SUBPOPULATION; VACCINE PRODUCTION;

ALLERGENS; ANIMALS; AUTOIMMUNE DISEASES; BEE VENOMS; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; GLYCOPROTEINS; HUMANS; HYPERSENSITIVITY; IMMUNE TOLERANCE; IMMUNOTHERAPY; MICE; PEPTIDES; PHOSPHOLIPASES A; RANDOMIZED CONTROLLED TRIALS; T-LYMPHOCYTE SUBSETS; VACCINES, SUBUNIT;

EID: 29944436179     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.4.6.881     Document Type: Review

References (70)

1. Bousquet J, Lockey R, Malling HJ et al. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American Academy of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. 81(5), 401-405 (1998).
2. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 302(6771), 265-269 (1991).
3. Varney VA, Edwards J, Tabbah K, Brewster H, Mavroleon G, Frew AJ. Clinical efficacy of specific immunotherapy to cat dander: a double-blind placebo-controlled trial. Clin. Exp. Allergy 27(8), 860-867 (1997).
4. Durham SR, Walker SM, Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341(7), 468-475 (1999).
5. Golden DB, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: extended observations. J. Allergy Clin. Immunol. 101(3), 298-305 (1998).
6. Lerch E, Muller UR. Long-term protection after stopping venom immunotherapy: results of re-stings in 200 patients. J. Allergy Clin. Immunol. 101(5), 606-612 (1998).
7. Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy 54(10), 1022-1041 (1999).
8. Borchers AT, Keen CL, Gershwin ME. Fatalities following allergen immunotherapy. Clin. Rev. Allergy Immunol. 27(2), 147-158 (2004).
9. Kay AB. Allergy and allergic diseases. First of two parts. N. Engl. J. Med. 344(1), 30-37 (2001).
10. + T cells. J. Exp. Med. 183(6), 2669-2674 (1996).
11. Weiner HL. Induction and mechanism of action of transforming growth factor-β-secreting Th3 regulatory cells. Immunol. Rev. 182, 207-214 (2001).
12. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J. Exp. Med. 157(5), 1434-1447 (1983). First study to report the induction of antigen-specific nonresponsiveness using peptides cultured with human T-cell clones.
13. Essery G, Feldmann M, Lamb JR. Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes. Immunology 64(3), 413-417 (1988).
14. O'Hehir RE, Aguilar BA, Schmidt TJ, Gollnick SO, Lamb JR. Functional inactivation of Dermatophagoides spp. (house dust mite) reactive human T-cell clones. Clin. Exp. Allergy 21(2), 209-215 (1991).
15. O'Hehir RE, Yssel H, Verma S, de Vries JE, Spits H, Lamb JR. Clonal analysis of differential lymphokine production in peptide and superantigen induced T cell anergy. Int. Immunol. 3(8), 819-826 (1991).
16. Gammon G, Dunn K, Shastri N, Oki A, Wilbur S, Sercarz EE. Neonatal T-cell tolerance to minimal immunogenic peptides is caused by clonal inactivation. Nature 319(6052), 413-415 (1986). One of the first peptide therapy studies in mice.
17. Clayton JP, Gammon GM, Ando DG, Kono DH, Hood L, Sercarz EE. Peptide-specific prevention of experimental allergic encephalomyelitis. Neonatal tolerance induced to the dominant T cell determinant of myelin basic protein. J. Exp. Med. 169(5), 1681-1691 (1989).
18. Critchfield JM, Racke MK, Zuniga-Pflucker JC et al. T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263(5150), 1139-1143 (1994).
19. Gaur A, Wiers B, Liu A, Rothbard J, Fathman CG. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 258(5087), 1491-1494 (1992).
20. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int. Immunol. 5(9), 1159-1165 (1993).
21. Burkhart C, Liu GY, Anderton SM, Metzler B, Wraith DC. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int. Immunol. 11(10), 1625-1634 (1999).
22. Anderton SM, Burkhart C, Liu GY, Metzler B, Wraith DC. Antigen-specific tolerance induction and the immunotherapy of experimental autoimmune disease. Novartis Found. Symp. 215, 120-131 (1998).
23. Ku G, Kronenberg M, Peacock DJ et al. Prevention of experimental autoimmune arthritis with a peptide fragment of type II collagen. Eur. J. Immunol. 23(3), 591-599 (1993).
24. Staines NA, Harper N, Ward FJ, Malmstrom V, Holmdahl R, Bansal S. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184-198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin. Exp. Immunol. 103(3), 368-375 (1996).
25. Prakken BJ, van Der ZR, Anderton SM, van Kooten PJ, Kuis W, van Eden W. Peptide-induced nasal tolerance for a mycobacterial heat shock protein 60 T cell epitope in rats suppresses both adjuvant arthritis and nonmicrobially induced experimental arthritis. Proc. Natl Acad. Sci. USA 94(7), 3284-3289 (1997).
26. Chu CQ, Londei M. Differential activities of immunogenic collagen type II peptides in the induction of nasal tolerance to collagen-induced arthritis. J. Autoimmun. 12(1), 35-42 (1999).
27. Bayrak S, Mitchison NA. Bystander suppression of murine collagen-induced arthritis by long-term nasal administration of a self type II collagen peptide. Clin. Exp. Immunol. 113(1), 92-95 (1998).
28. Daniel D, Wegmann DR. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl Acad. Sci. USA 93(2), 956-960 (1996).
29. Bockova J, Elias D, Cohen IR. Treatment of NOD diabetes with a novel peptide of the hsp60 molecule induces Th2-type antibodies. J. Autoimmun. 10(4), 323-329 (1997).
30. Tian J, Atkinson MA, Clare-Salzler M et al. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 183(4), 1561-1567 (1996).
31. Karachunski PI, Ostlie NS, Okita DK, Conti-Fine BM. Prevention of experimental Myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. J. Clin. Invest. 100(12), 3027-3035 (1997).
32. Paas-Rozner M, Sela M, Mozes E. A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating. Proc. Natl. Acad. Sci. USA 100(11), 6676-6681 (2003).
33. Zou LP, Zhu J, Deng GM et al. Treatment with P2 protein peptide 57-81 by nasal route is effective in Lewis rat experimental autoimmune neuritis. J. Neuroimmunol. 85(2), 137-145 (1998).
34. Briner TJ, Kuo MC, Keating KM, Rogers BL, Greenstein JL. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc. Natl Acad. Sci. USA 90(16), 7608-7612 (1993). First murine model of peptide therapy in allergy.
35. Hoyne GF, O'Hehir RE, Wraith DC, Thomas WR, Lamb JR. Inhibition of T cell and antibody responses to house dust mite allergen by inhalation of the dominant T cell epitope in naive and sensitized mice. J. Exp. Med. 178(5), 1783-1788 (1993).
36. Bauer L, Bohle B, Jahn-Schmid B et al. Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1. Clin. Exp. Immunol. 107(3), 536-541 (1997).
37. Astori M, von Garnier C, Kettner A, Dufour N, Corradin G, Spertini F. Inducing tolerance by intranasal administration of long peptides in naive and primed CBA/J mice. J. Immunol. 165(6), 3497-3505 (2000).
38. Chai JG, James E, Dewchand H, Simpson E, Scott D. Transplantation tolerance induced by intranasal administration of HY peptides. Blood 103(10), 3951-3959 (2004). Describes low-dose peptide tolerance in a murine model.
39. Apostolou I, Von Boehmer H. In vivo instruction of suppressor commitment in naive T cells. J. Exp. Med. 199(10), 1401-1408 (2004). Describes the induction of regulatory T-cells after chronic low-dose peptide administration in an animal model.
40. Norman PS, Ohman JL, Long AA et al. Treatment of cat allergy with T-cell reactive peptides. Am. J. Respir. Crit. Care Med. 154, 1623-1628 (1996). First clinical study of peptide therapy.
41. Marcotte GV, Braun CM, Norman PS et al. Effects of peptide therapy on ex vivo T-cell responses. J. Allergy Clin. Immunol. 101, 506-513 (1998).
42. Pene J, Desroches A, Paradis L et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T-cells of patients allergic to cats. J. Allergy Clin. Immunol. 102, 571-578 (1998).
43. Simons FE, Imada M, Li Y, Watson WT, HayGlass KT. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int. Immunol. 8(12), 1937-1945 (1996).
44. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of ALLERVAX® CAT in cat allergic patients. Clin. Immunol. 93(3), 222-231 (1999).
45. Haselden BM, Kay AB, Larche M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J. Exp. Med. 189(12), 1885-1894 (1999). First demonstration that peptide challenge can activate effector T-cells and induce airway narrowing.
46. Oldfield WL, Kay AB, Larche M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J. Immunol. 167(3), 1734-1739 (2001).
47. Alexander C, Ying S, Kay B, Larche M. Fel d 1-derived T cell peptide therapy induces recruitment of CD4CD25; CD4 interferon-γ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin. Exp. Allergy 35(1), 52-58 (2005).
48. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 360(9326), 47-53 (2002). A double-blind, placebo-controlled trial of Fel d 1 peptides in cat allergic asthmatic subjects.
49. Muller U, Helbling A, Berchtold E. Immunotherapy with honeybee venom and yellow jacket venom is different regarding efficacy and safety. J. Allergy Clin. Immunol. 89(2), 529-535 (1992).
50. Müller U, Akdis CA, Fricker M et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J. Allergy Clin. Immunol. 101, 747-754 (1998). First study of peptide immunotherapy in bee venom allergy.
51. Fellrath JM, Kettner A, Dufour N et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J. Allergy Clin. Immunol. 111(4), 854-861 (2003).
52. Webb S, Morris C, Sprent J. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 63(6), 1249-1256 (1990).
53. + T cells. Eur. J. Immunol. 23(12), 3306-3311 (1993).
54. Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71(7), 1065-1068 (1992).
55. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J. Exp. Med. 157(5), 1434-1447 (1983).
56. Bal V, McIndoe A, Denton G et al. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur. J. Immunol. 20(9), 1893-1897 (1990).
57. Rocken M, Shevach EM. Immune deviation - the third dimension of nondeletional T cell tolerance. Immunol. Rev. 149, 175-194 (1996).
58. Verhoef A, Alexander C, Kay AB, Larche M. T-cell epitope immunotherapy induces a CD4(+) T-cell population with regulatory activity. PLoS Med. 2(3), 78 (2005). First study to describe the generation of functional antigen-specific regulatory T-cells after a clinical intervention.
59. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nature Med. 11(Suppl. 4), S69-S76 (2005). Detailed review of peptide immunotherapy in allergy and autoimmunity.
60. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, Phase II trial. Lancet 358(9295), 1749-1753 (2001). First report of peptide therapy in Type I diabetes in humans.
61. Akdis CA, Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J. 13(6), 603-609 (1999).
62. Tarzi M, Klunker S, Texier C et al. Induction of interleukin-10 and suppressor of cytokine signaling-3 gene expression following peptide immunotherapy. Clin. Exper. Allergy (2005).
63. Prakken BJ, Samodal R, Le TD, Giannoni F, Yun GP, Scavulli J. Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc. Natl Acad. Sci. USA 101(12), 4228-4233 (2004). Report of mechanistic observations in a clinical trial of peptide immunotherapy in rheumatoid arthritis.
64. Ali FR, Oldfield WL, Higashi N, Larche M, Kay AB. Late asthmatic reactions induced by inhalation of allergen-derived T-cell peptides. Am. J. Respir. Crit. Care Med. 169(1), 20-26 (2004).
65. Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc. Natl Acad. Sci. USA 96(26), 15050-15055 (1999).
66. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003).
67. Niederberger V, Horak F, Vrtala S et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl Acad. Sci. USA 101(Suppl. 2), 14677-14682 (2004).
68. Hirahara K, Tatsuta T, Takatori T et al. Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens. J. Allergy Clin. Immunol. 108(1), 94-100 (2001).
69. Focke M, Mahler V, Ball T et al. Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination. FASEB J. 15(11), 2042-2044 (2001).
70. Janssen EM, van Oosterhout AJ, van Rensen AJ, van Eden W, Nijkamp FP, Wauben MH. Modulation of Th2 responses by peptide analogues in a murine model of allergic asthma: amelioration or deterioration of the disease process depends on the Th1 or Th2 skewing characteristics of the therapeutic peptide. J. Immunol. 164(2), 580-588 (2000).